Home Tags DS-1062

Tag: DS-1062

General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2020: Late-Breaking Data for HER3 Directed ADC Patritumab Deruxtecan in...

Data for patritumab deruxtecan (U3-1402; Daiichi Sankyo) and fam-trastuzumab deruxtecan-nxki* (Enhertu®; Daiichi Sankyo/AstraZeneca), two antibody-drug conjugates (ADC) based on Daiichi Sankyo's proprietary DXd ADC...

Daiichi Sankyo and AstraZeneca Agree on Global Development and Commercialization for...

Daiichi Sankyo and AstraZeneca confirmed entering into a global development and commercialization agreement for datopotamab deruxtecan also know as DS-1062, a TROP2 directed DXd...
Featured Image: Women and the power to fight breast cancer Courtesy: © 2017. Fotolia. Used with permission.

Daiichi Sankyo and Gustave Roussy Sign Multi-year and Multi-study Adaptive Phase...

Daiichi Sankyo and Gustave Roussy have signed a multi-year, multi-study research collaboration for the ongoing development of DS-1062 and patritumab deruxtecan (previously known as U3-1402),...
Featured Image: Scientist in Biomedical Laboratory. Courtesy 2019 Fotolia. used with permission.

Rapid Advances in the Development of Novel ADCs Targeting B7-H3 and...

With five antibody-drug conjugates (ADC) having received approval from the United States Food and Drug Administration (FDA) and other regulators around the world and...

WCLC 2019: Daiichi Sankyo to Present Late-breaking Results from U3-1402 and...

The World Health Organization (WHO) estimates that lung cancer causes 1.59 million deaths globally per year. Non-small cell lung cancer (NSCLC) accounts for 80%–90%...

Phase I Study of DS-1062 in Patients with Advanced Non-Small Cell...

The first patient has been dosed in a phase I study assessing the safety and tolerability of DS-1062, an investigational trophoblast cell-surface antigen 2...